Allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic

Class

Allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic progenitor cell therapy, implanted bilaterally into the brain

Pathway

Cell replacement of lost midbrain dopaminergic neurons to restore striatal dopaminergic signaling

Notes

original target text: Allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic progenitor cell therapy, implanted bilaterally into the brain

This mechanism describes a cell replacement therapy for Parkinson's disease, a movement disorder caused by progressive loss of dopamine-producing neurons in a midbrain region called the substantia nigra. These neurons normally send projections to the striatum, a deep brain structure that coordinates movement, and their depletion produces the tremor, rigidity, and slowness characteristic of the disease. Rather than supplementing dopamine pharmacologically, this approach seeks to physically replace the missing neurons. Dopaminergic progenitor cells are generated in the laboratory from induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed to an embryonic-like state capable of becoming almost any cell type. These progenitors are guided through a differentiation process toward a midbrain dopaminergic identity, then surgically implanted directly into both sides of the brain, typically into the striatum, where they are intended to mature, survive, and re-establish local dopamine signaling. Because the cells are allogeneic, meaning derived from a donor rather than the patient, they can be manufactured in advance and used across many recipients, offering a scalable alternative to patient-specific cell sources. This mechanism is broadly relevant to Parkinson's disease and other conditions defined by focal neuronal loss where restoring a specific cell population, rather than only modulating signaling, is the therapeutic goal.